Similar articles

• TIGIT immune checkpoint blockade restores CD8⁺ T-cell immunity against multiple myeloma.

  Guillerey C, Harjunpää H, Carrié N, Kassem S, Teo T, Miles K, Krumeich S, Weulersse M, Cuisinier M, Stannard K, Yu Y, Minnie SA, Hill GR, Dougall WC, Avet-Loiseau H, Teng MWL, Nakamura K, Martinet L, Smyth MJ. Guillerey C, et al. Blood. 2018 Oct 18;132(16):1689-1694. doi: 10.1182/blood-2018-01-825265. Epub 2018 Jul 9. Blood. 2018. PMID: 29986909
• Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade.

  Minnie SA, Kuns RD, Gartlan KH, Zhang P, Wilkinson AN, Samson L, Guillerey C, Engwerda C, MacDonald KPA, Smyth MJ, Markey KA, Vuckovic S, Hill GR. Minnie SA, et al. Blood. 2018 Oct 18;132(16):1675-1688. doi: 10.1182/blood-2018-01-825240. Epub 2018 Aug 28. Blood. 2018. PMID: 30154111
• CD155T/TIGIT Signaling Regulates CD8⁺ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer.

  He W, Zhang H, Han F, Chen X, Lin R, Wang W, Qiu H, Zhuang Z, Liao Q, Zhang W, Cai Q, Cui Y, Jiang W, Wang H, Ke Z. He W, et al. Cancer Res. 2017 Nov 15;77(22):6375-6388. doi: 10.1158/0008-5472.CAN-17-0381. Epub 2017 Sep 7. Cancer Res. 2017. PMID: 28883004
• TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

  Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. Dougall WC, et al. Immunol Rev. 2017 Mar;276(1):112-120. doi: 10.1111/imr.12518. Immunol Rev. 2017. PMID: 28258695 Review.
• Targeting the "PVR-TIGIT axis" with immune checkpoint therapies.

  Gorvel L, Olive D. Gorvel L, et al. F1000Res. 2020 May 13;9:F1000 Faculty Rev-354. doi: 10.12688/f1000research.22877.1. eCollection 2020. F1000Res. 2020. PMID: 32489646 Free PMC article. Review.